bpc 157 ulcerative colitis phase ii Pentadecapeptide 157, in Clinical Trials as a Therapy for Inflammatory Bowel Disease (PL14736), Is Effective in the Healing BPC-157 vs TB-500: Complete Comparison

Nexium Lawsuits Several lawsuits have been filed nationwide alleging Nexiums manufacturer, AstraZeneca, responsible for the serious damages caused to patients as a consequence of long-term (one year or more) Nexium use

Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study

It was identified through a medicinal chemistry programme at the University of Texas Health Science Center as the lead NNMT inhibitor candidate among a series of 1-methylquinolinium analogues bearing primary amine substitutions, selected for its combination of high passive membrane permeability (confirmed in PAMPA assays), high active transport membrane permeability (confirmed in bidirectional Caco-2 cell assays), potent NNMT inhibitory activity, and high selectivity including confirmed absence of inhibitory effects on related SAM-dependent methyltransferases or enzymes in the NAD+ salvage pathway

doi: 10.1007/s12038-013-9385-9, PMID: [DOI] [PubMed] [Google Scholar] Ibrahim M